OR WAIT 15 SECS
If pharma is seen as a genuine contributor to the policy debate on comparative effectiveness, it could influence funding, pricing, and coverage decisions
There are forces transforming the healthcare system—forces I think of as powerful trains coming down the track. Most attempts to stop them will be futile, so the only choice pharma companies are left with, as Lee Iacocca used to say in his Chrysler advertisements, is to "lead, follow, or get out of the way." To "just say no" is not a viable option.
When it comes to healthcare reform, pharma is sometimes its own worst enemy. A friend of mine in the industry put it this way: "We seldom pay attention to health policy until there is a crisis, and then it is too late. Too often our leaders seem to think that the best course is to do nothing." There may be times when doing nothing is a good strategy—but this is not one of them.
Most of the unstoppable trains that will transform the healthcare system over the next decade are very familiar—evidence-based medicine, quality measures, pay-for-performance, price transparency, electronic health records and other health-information technology, genomics, and new medical technologies. There's now much talk of a comparative-effectiveness (CE) board to consider the cost-effectiveness of different treatments, diagnostics, and procedures. And there's the growth of high-deductible health plans. I doubt these are passing fads.
Advocates of these new developments argue persuasively that they will improve the quality, efficiency, and cost-effectiveness of medical care. However, many people in the industry are nervous that they'll be used to beat up the industry and force it to lower prices. They fear that:
Let's consider the issue of cost-effectiveness. At a comparative-effectiveness forum last November, there was a consensus that a CE board will form to review, fund, and conduct studies. The additional value of the board would come from disseminating its findings and coordinating efforts to integrate these findings into practice.
How should pharma companies react to this concept? They could oppose it ("just say no"). Or, they could support it with enthusiasm and play a leadership role in shaping and designing it. Many other players will want to have a voice in shaping this CE board. If the pharmaceutical industry is seen as a genuine contributor to the policy debate, it could exert substantial influence on many of the details. How will it be funded? What organizations can influence or control it? What is the involvement of CMS, FDA, the private sector? How much independence will it have? How much power will it have? What role will it have in relation to the development of clinical guidelines? Will it make coverage decisions? Will it get involved in price negotiations?
It is possible that a CE board would provide an opportunity for the industry to demonstrate the value of its products, in both financial and human terms. On the other hand, such a board focused mainly on drug prices could not only damage the profitability of the industry but ultimately limit public access to new and innovative, but expensive, drugs.
If I had figured out how the pharma industry should play all its cards, I would be a very highly paid consultant. But what I do know is that companies should see this as an opportunity to be seized—to help drive the train rather than to throw itself on the tracks.
Humphrey Taylor is chairman of the Harris Poll, Harris Interactive. He can be reached at firstname.lastname@example.org